Erik C. Dreaden joined the Wallace H. Coulter Department of Biomedical Engineering at Georgia Institute of Technology and Emory University in 2017. Dr. Dreaden also holds a joint faculty appointment in the Department of Pediatrics at the Emory University School of Medicine where he collaborates with researchers at Children's Healthcare of Atlanta and the Aflac Center for Cancer and Blood Disorders. Dr. Dreaden's research seeks to apply principles of molecular and nanoscale engineering to improve the therapeutic potential of drug combinations, vaccines, and immunotherapies directed against pediatric and adult cancers. 

Prior to joining Emory and Georgia Tech, Dr. Dreaden was a postdoctoral fellow at the Koch Institute for Integrative Cancer Research at MIT, where his research focused on the development of polymer-based technologies for nucleic acid and rational combination cancer therapies. 

Dr. Dreaden is a member of the Cancer Immunology Research Program at the Winship Cancer Institute of Emory University. He also holds memberships in the Biomedical Engineering Society, American Institute of Chemical Engineers, American Association of Cancer Research, Materials Research Society, American Association for the Advancement of Science, and American Chemical Society.

Dr. Simone Douglas-Green (@DrBlackBoots on Twitter/X and Instagram) is a new Assistant Professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, where she has been named a BME Distinguished Faculty Fellow. She received her B.S. in Biomedical Engineering from the University of Miami, and her Ph.D. in Biomedical Engineering from the joint program at Georgia Tech and Emory University. Dr. Douglas-Green’s professional and scholarly development as a doctoral and postdoctoral trainee has been supported by a number of awards including the Alfred P. Sloan Foundation's Minority Ph.D. (MPHD) Fellowship, NASEM Ford Foundation Postdoctoral Fellowship, and Burroughs Wellcome Fund Postdoctoral Enrichment Program (PDEP). The Douglas-Green Lab focuses on developing tools/techniques to study how biology interacts with nanoparticles with an emphasis on understanding person and disease specific proteins coronas. Her goal is to train the next generation of engineers to be “EPIC”- engineering with purpose, inclusivity and compassion.

Dr. Dixon began at Georgia Tech in August 2009 as an Assistant Professor. Prior to his current appointment, he was a staff scientist at Ecole Polytechnique Federal de Lausanne (Swiss Federal Institute of Technology - Lausanne) doing research on tissue-engineered models of the lymphatic system. Dr. Dixon received his Ph.D. in biomedical engineering while working in the Optical Biosensing Laboratory, where he developed an imaging system for measuring lymphatic flow and estimating wall shear stress in contracting lymphatic vessels. 

Dr. Dixon's research focuses on elucidating and quantifying the molecular aspects that control lymphatic function as they respond to the dynamically changing mechanical environment they encounter in the body. Through the use of tissue-engineered model systems and animal models, our research is shedding light on key functions of lymphatic transport, and the consequence of disease on these functions. One such function is the lymphatic transport of dietary lipid from the intestine to the circulation. Recent evidence from our lab suggests that this process involves active uptake into lymphatics by the lymphatic endothelial cells. There are currently no efficacious cures for people suffering from lymphedema, and the molecular details connecting lymphedema severity with clinically observed obesity and lipid accumulation are unknown. Knowledge of these mechanisms will provide insight for planning treatment and prevention strategies for people facing lipid-lymphatic related diseases. 

Intrinsic to the lymphatic system are the varying mechanical forces (i.e., stretch, fluid shear stress) that the vessels encounter as they seek to maintain interstitial fluid balance and promote crucial transport functions, such as lipid transport and immune cell trafficking. Thus, we are also interested in understanding the nature of these forces in both healthy and disease states, such as lymphedema, in order to probe the biological response of the lymphatic system to mechanical forces. The complexity of these questions requires the development of new tools and technologies in tissue engineering and imaging. In the context of exploring lymphatic physiology, students in Dr. Dixon's laboratory learn to weave together techniques in molecular and cell biology, biomechanics, imaging, computer programming, and image and signal processing to provide insight into the regulation of lymphatic physiology. Students in the lab also have the opportunity to work in an interdisciplinary environment, as we collaborate with clinicians, life scientists, and other engineers, thus preparing the student for a career in academia and basic science research, or a career in industry.

Aditi Das did her BSc. (Hons.) Chemistry from St. Stephen's College Delhi, followed by M.S. (Chemistry) from I.I.T (Kanpur). She received her Ph.D. in Chemistry from Princeton University. She did post-doctoral work with Prof. Steve Sligar. She joined University of Illinois, Urbana-Champaign (UIUC) as a tenure track assistant professor in 2012. In 2019, she was promoted to associate professor with tenure. In 2022, she joined School of Chemistry and Biochemistry at Georgia Institute of Technology as an associate professor with tenure. Her research is in the area of enzymology of oxygenases that are involved lipid metabolism and cannabinoid metabolism.

Das is recipient of an American Heart Associate (AHA) career award and has been funded by National Institute of Health (NIH - NIGMS, NIDA and NCCIH), USDA, and National Multiple Sclerosis Society (NMSS). Her research was recognized by several National awards: Young Investigator award From Eicosanoid Research Foundation, Mary Swartz Rose Young Investigator Award and E.L.R. Stokstad award from American Society for Nutrition (ASN) for outstanding research on bioactive compounds for human health. She is also the recipient of Zoetis Research Excellence Award from her college. She was a co-organizer of the International Conference on Cytochrome P450. Recently her laboratory contributed several papers on cannabinoid metabolism by p450s. In recognition of this work, she was awarded El Sohly award from the ACS-Cannabis division for excellence in Cannabis research and is invited to give plenary lecture at ISSX meeting.  Das is also a standing study section member of BBM NIH study section. 

James Dahlman is a bioengineer / molecular engineer whose work lies at the interface of chemistry, nanotechnology, genomics, and gene editing. His lab focuses on targeted drug delivery, in vivo gene editing, Cas9 therapies, siRNA therapies, and developing new technologies to improve biomaterial design. 

The DahlmanLab is known for applying 'big data' technologies to nanomedicine. The lab is pioneering DNA barcoded nanoparticles; using DNA barcodes, >200 nanoparticles can be analyzed simultaneously in vivo. These nanoparticles are studied directly in vivo, and used to deliver targeted therapies like siRNA, mRNA, or Cas9. As a result of this work, James was named 1 of the 35 most innovative people under the age of 35 by MIT Technnology Review in 2018. James has won many national / international awards, and has published in Science, Nature Nanotechnology, Nature Biotechnology, Nature Cell Biology, Cell, Science Translational Medicine, PNAS, JACS, ACS Nano, Nano Letters, and other journals. James has also designed nanoparticles that efficiently deliver RNAs to the lung and heart. These nanoparticles can deliver 5 siRNAs at once in vivo, and are under consideration for clinical development. As a result, the lab has an interest in immunology and vascular biology. 

James supports entirely new research students come up with independently. To this end, DahlmanLab students learn how to (i) generate new ideas, (ii) select the good ones, and (iii) efficiently test whether the good ideas will actually work. 

Dahlman Lab students learn how to design/characterize/administer nanoparticles, how to isolate different cell types in vivo, how to rationally design DNA to record information, Cas9 therapies, and deep sequencing. As a result, the lab is an interdisciplinary group with students that have backgrounds in medicinal chemistry, BME, bioinformatics, biochemistry, and other fields. The lab welcomes students with all types of scientific backgrounds. The lab firmly stands by students, independent of their personal beliefs, preferences, or backgrounds.

Marcus T Cicerone received his Ph.D. from the University of Wisconsin – Madison in 1994, under the direction of Mark Ediger. He spent three years at Johnson & Johnson Clinical Diagnostics, served as a visiting teaching professor at Brigham Young University for two years, and subsequently joined the National Institute of Standards and Technology in 2001, where he remained for 18 years, serving as a group leader and project leader. In January 2019 he joined the Georgia Institute of Technology as a Professor of Chemistry. 

Professor Cicerone is a fellow of American Physical Society, and has received several awards for his efforts in coherent Raman-based biological imaging and for his work in dynamics of liquids and amorphous solids. These include a Johnson & Johnson Director’s Research Award, two Department of Commerce Bronze metals, the 2015 Washington Academy of Sciences Physical & Biological Sciences Award, and the 2017 Arthur S. Flemming Award.

Julie Champion is the William R. McLain Endowed Term Professor in the School of Chemical and Biomolecular Engineering at Georgia Institute of Technology. She earned her B.S.E. in chemical engineering from the University of Michigan and Ph.D. in chemical engineering at the University of California Santa Barbara. She was an NIH postdoctoral fellow at the California Institute of Technology. Champion is a fellow of the American Institute for Medical and Biological Engineering and has received awards including American Chemical Society Women Chemists Committee Rising Star, NSF BRIGE Award, Georgia Tech Women in Engineering Faculty Award for Excellence in Teaching, Georgia Tech BioEngineering Program Outstanding Advisor Award. Professor Champion’s current research focuses on design and self-assembly of functional nanomaterials made from engineered proteins for applications in immunology, cancer, and biocatalysis.

Sam Brown's lab studies the multi-scale dynamics of infectious disease. Their goal is to improve the treatment and control of infectious diseases through a multi-scale understanding of microbial interactions. Their approach is highly interdisciplinary, combining theory and experiment, evolution, ecology and molecular microbiology in order to understand and control the multi-scale dynamics of bacteria pathogens.

Blair Brettmann received her B.S. in chemical engineering at the University of Texas at Austin in 2007. She received her Master’s in chemical engineering practice from MIT in 2009 following internships at GlaxoSmithKline (Upper Merion, PA) and Mawana Sugar Works (Mawana, India). Blair received her Ph.D. in chemical engineering at MIT in 2012 working with the Novartis-MIT Center for Continuous Manufacturing under Professor Bernhardt Trout. Her research focused on solid-state characterization and application of pharmaceutical formulations prepared by electrospinning. Following her Ph.D., Brettmann worked as a research engineer for Saint-Gobain Ceramics and Plastics for two years. While at Saint-Gobain she worked on polymer-based wet coatings and dispersions for various applications, including window films, glass fiber mats and architectural fabrics. Later, Brettmann served as a postdoctoral researcher in the Institute for Molecular Engineering at the University of Chicago with Professor Matthew Tirrell. Currently, Brettmann is an assistant professor with joint appointments in chemical and biomolecular engineering and Materials Science and Engineering at Georgia Tech.

Andreas (Andy) S. Bommarius is a professor of Chemical and Biomolecular Engineering as well of Chemistry and Biochemistry at the Georgia Institute of Technology in Atlanta, GA.  He received his diploma in Chemistry in 1984 at the Technical University of Munich, Germany and his Chemical Engineering B.S. and Ph.D. degrees in 1982 and 1989 at MIT, Cambridge, MA.

From 1990-2000, he led the Laboratory of Enzyme Catalysis at Degussa (now Evonik) in Wolfgang, Germany, where his work ranged from immobilizing homogenous catalysts in membrane reactors to large-scale cofactor-regenerated redox reactions to pharma intermediates.

At Georgia Tech since 2000, his research interests cover green chemistry and biomolecular engineering, specifically biocatalyst development and protein stability studies.  His lab applies data-driven protein engineering to improve protein properties on catalysts ranging from ene and nitro reductases to cellobiohydrolases.  Bommarius has guided the repositioning of the curriculum towards Chemical and Biomolecular Engineering by developing new courses in Process Design, Biocatalysis and Metabolic Engineering, as well as Drug Design, Development, and Delivery (D4), an interdisciplinary course with Mark Prausnitz.

Andy Bommarius in 2008 became a Fellow of the American Institute of Medical and Biological Engineering.  Since 2010, he is Director of the NSF-I/UCR Center for Pharmaceutical Development (CPD), a Center focusing on process development, drug substance and product stability, and novel analytical methods for the characterization of drug substances and excipients.